IBM Canada has partnered with Boehringer Ingelheim, a Canadian pharmaceutical company, to test the use of blockchain in clinical record keeping, as stated in the company’s press release.

The partnership between the duo is intended to check if integrating blockchain technology with clinical records keeping maintains the data integrity and transparency or not, along with ensuring patient safety. The collaboration is also aimed at automating the data recording process and reducing the upfront costs.

Dr. Uli Broedl, Vice President of Medical and Regulatory Affairs at Boehringer Ingelheim, has stated that the collaboration with IBM will help them address the issues involved in clinical trial ecosystem. It is expected that blockchain will ensure trust and transparency between stakeholders by eliminating the inefficiencies associated with the previous system.

You may also like: IBM Research Aligns with Hello Tractor to Improve African AgriBusiness with Blockchain